Literature DB >> 1681541

Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death.

N A Berger1, S Chatterjee, J A Schmotzer, S R Helms.   

Abstract

We have shown previously a good correlation between etoposide-induced sister chromatid exchanges (SCE) and cytotoxicity. A semisynthetic derivative of podophyllotoxin, etoposide is also called Vepesid (Bristol; code designation VP-16-213, abbreviated VP-16). Since SCE represent DNA recombinational events, we hypothesized that VP-16-induced SCE might result in nonhomologous recombination in which segments of DNA were either deleted or added, leading to an alteration of gene sequences responsible for essential cell proteins. Alterations of such essential genes and consequent interference with formation of their products could consequently lead to cell death. To evaluate whether VP-16 treatment caused sufficient levels of DNA sequence alterations to interfere with gene product formation, we isolated hypoxanthine (guanine) phosphoribosyltransferase (HPRT)-deficient mutants from Chinese hamster V79 cells grown in the presence or absence of VP-16. DNA from 3 spontaneous mutants and 10 VP-16-induced mutants was analyzed by Southern blot hybridization to a full-length hamster HPRT cDNA probe. Most of the VP-16-induced mutants showed partial deletions and/or rearrangements of the HPRT gene. In contrast, spontaneous mutants showed negligible deletions or rearrangements. These results provide strong support for our hypothesis that deletion of genetic sequences may constitute an important component of the mechanism of VP-16-induced cell death.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1681541      PMCID: PMC52585          DOI: 10.1073/pnas.88.19.8740

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells.

Authors:  Y Pommier; D Kerrigan; J M Covey; C S Kao-Shan; J Whang-Peng
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

2.  Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells.

Authors:  J Markovits; Y Pommier; D Kerrigan; J M Covey; E J Tilchen; K W Kohn
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

Review 3.  Recent studies of DNA topoisomerases.

Authors:  J C Wang
Journal:  Biochim Biophys Acta       Date:  1987-06-06

4.  DNA topoisomerases as targets for cancer therapy.

Authors:  W E Ross
Journal:  Biochem Pharmacol       Date:  1985-12-15       Impact factor: 5.858

5.  The nature of mutants induced by ionising radiation in cultured hamster cells. III. Molecular characterization of HPRT-deficient mutants induced by gamma-rays or alpha-particles showing that the majority have deletions of all or part of the hprt gene.

Authors:  J Thacker
Journal:  Mutat Res       Date:  1986-05       Impact factor: 2.433

6.  Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213.

Authors:  B Drewinko; B Barlogie
Journal:  Cancer Treat Rep       Date:  1976-09

7.  Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors.

Authors:  Y Pommier; R E Schwartz; L A Zwelling; D Kerrigan; M R Mattern; J Y Charcosset; A Jacquemin-Sablon; K W Kohn
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

Review 8.  DNA topoisomerase II as a target of antineoplastic drug therapy.

Authors:  L A Zwelling
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

9.  DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.

Authors:  B H Long; S T Musial; M G Brattain
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

10.  Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells.

Authors:  B Singh; R S Gupta
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

View more
  9 in total

1.  The PKZ1 recombination mutation assay: a sensitive assay for low dose studies.

Authors:  P J Sykes; A A Morley; A M Hooker
Journal:  Dose Response       Date:  2006-08-19       Impact factor: 2.658

Review 2.  DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.

Authors:  Y Pommier
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei.

Authors:  I I Gromova; B Thomsen; S V Razin
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-03       Impact factor: 11.205

4.  Poly(ADP-ribose) polymerase: a guardian of the genome that facilitates DNA repair by protecting against DNA recombination.

Authors:  S Chatterjee; S J Berger; N A Berger
Journal:  Mol Cell Biochem       Date:  1999-03       Impact factor: 3.396

5.  Etoposide pathway.

Authors:  Jun Yang; Alessia Bogni; Erin G Schuetz; Mark Ratain; M Eileen Dolan; Howard McLeod; Li Gong; Caroline Thorn; Mary V Relling; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

Review 6.  Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia.

Authors:  J Yang; A Bogni; C Cheng; W K Bleibel; X Cai; Y Fan; W Yang; J C C Rocha; D Pei; W Liu; M E Dolan; C-H Pui; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2008-05-28       Impact factor: 6.875

7.  Preferential induction of MLL(Mixed Lineage Leukemia) rearrangements in human lymphocyte cultures treated with etoposide.

Authors:  María Sol Brassesco; Ana Paula Montaldi; Elza Tiemi Sakamoto-Hojo
Journal:  Genet Mol Biol       Date:  2009-03-01       Impact factor: 1.771

Review 8.  Utility of a next-generation framework for assessment of genomic damage: A case study using the pharmaceutical drug candidate etoposide.

Authors:  John Nicolette; Mirjam Luijten; Jennifer C Sasaki; Laura Custer; Michelle Embry; Roland Froetschl; George Johnson; Gladys Ouedraogo; Raja Settivari; Veronique Thybaud; Kerry L Dearfield
Journal:  Environ Mol Mutagen       Date:  2021-11-22       Impact factor: 3.579

9.  Allium sativum aqueous extract does not have chemo-protective effect on etoposide induced therapy-related DNA damage leading to Acute Myeloid Leukemia in albino-wistar rats.

Authors:  Ugochi F Ndiokwelu; Liasu A Ogunkanmi; Joseph B Minari; Ijeoma C Uzoma
Journal:  Afr Health Sci       Date:  2021-06       Impact factor: 0.927

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.